XYL - Danaher's Growth Machine Keeps On Roaring With No Slowdown In Sight For Bioproduction

• The Street expected a strong quarter from Danaher, and they got that and more, with strong growth across the business and significant margin leverage.
• Bioproduction remains a once-in-a-generation growth opportunity where Danaher has bought its leadership, including the recent deal for Aldevron to build up its plasmid DNA capabilities.
• PCR-based COVID-19 testing has remained strong for Cepheid, and the company is likewise leveraging pandemic-driven system placements across its full set of test offerings.
• EAS is recovering nicely, with particularly good growth in Product ID, but this business remains a sale/spin-off candidate.
• Danaher doesn't really lend itself to sober-minded quantitative valuation approaches, but the growth set-up remains top-notch.

For further details see: